Myriad Genetics, Inc. (NASDAQ:MYGN) had its target price upped by investment analysts at Morgan Stanley from $24.00 to $26.00 in a note issued to investors on Wednesday. The firm currently has an “underweight” rating on the stock. Morgan Stanley’s price target points to a potential downside of 13.65% from the company’s current price.

A number of other research analysts have also weighed in on the stock. BidaskClub lowered shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Zacks Investment Research raised shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a research note on Monday, July 17th. Barclays PLC decreased their price objective on shares of Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 9th. Jefferies Group LLC restated a “hold” rating and issued a $23.00 price objective (up from $21.00) on shares of Myriad Genetics in a report on Thursday, August 10th. Finally, Piper Jaffray Companies reiterated a “hold” rating and issued a $22.00 target price on shares of Myriad Genetics in a report on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Myriad Genetics currently has an average rating of “Hold” and a consensus target price of $28.10.

Myriad Genetics (MYGN) traded up $0.21 during midday trading on Wednesday, reaching $30.11. 736,176 shares of the company’s stock traded hands, compared to its average volume of 1,042,821. Myriad Genetics has a 12-month low of $15.15 and a 12-month high of $37.30. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.26 and a current ratio of 1.46. The stock has a market cap of $2,096.97, a PE ratio of 28.58, a price-to-earnings-growth ratio of 1.95 and a beta of 0.24.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, November 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.05. The firm had revenue of $190.20 million during the quarter, compared to analysts’ expectations of $183.52 million. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. Myriad Genetics’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.23 earnings per share. equities research analysts expect that Myriad Genetics will post 1.04 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Myriad Genetics, Inc. (MYGN) PT Raised to $26.00” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/08/myriad-genetics-inc-mygn-pt-raised-to-26-00.html.

In other Myriad Genetics news, Director John T. Henderson sold 30,000 shares of Myriad Genetics stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $30.30, for a total transaction of $909,000.00. Following the transaction, the director now directly owns 52,524 shares of the company’s stock, valued at $1,591,477.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.70% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of MYGN. BlackRock Inc. raised its position in shares of Myriad Genetics by 168,335.7% in the 1st quarter. BlackRock Inc. now owns 9,541,884 shares of the company’s stock worth $183,203,000 after purchasing an additional 9,536,219 shares during the last quarter. Thrivent Financial For Lutherans raised its position in Myriad Genetics by 7,026.7% in the 2nd quarter. Thrivent Financial For Lutherans now owns 2,742,340 shares of the company’s stock worth $70,862,000 after buying an additional 2,703,860 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Myriad Genetics by 59.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,642,820 shares of the company’s stock worth $50,742,000 after buying an additional 987,966 shares during the last quarter. Vanguard Group Inc. raised its position in Myriad Genetics by 16.8% in the 1st quarter. Vanguard Group Inc. now owns 6,251,030 shares of the company’s stock worth $120,020,000 after buying an additional 897,287 shares during the last quarter. Finally, PDT Partners LLC bought a new stake in shares of Myriad Genetics during the 2nd quarter valued at about $8,481,000.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Stock Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related stocks with our FREE daily email newsletter.